article · Journal of The Egyptian Society of Nephrology and Transplantation
Background Chronic kidney disease and end-stage renal disease (ESRD) are worldwide public health problems with increasing incidence and prevalence. Cardiovascular disease is the most common cause of morbidity and mortality among patients with ESRD. Hepatitis C virus (HCV) is a worldwide health problem. The prevalence of HCV infection among hemodialysis (HD) patients is generally much higher than that among the general population. This study aimed to compare serum levels of N-terminal probrain natriuretic peptide (NT-ProBNP) and its relation to diastolic dysfunction and Child–Pugh in HCV-positive and HCV-negative patients on HD. Patients and methods This cross-sectional study included 60 ESRD patients; group A, 30 HCV-positive patients on HD, and group B, 30 HCV-negative patients on HD. Routine laboratory investigations, serum NT-ProBNP, and echocardiography were done for all patients. Results HCV-positive patients had a substantially higher median serum level of NT-ProBNP (3424.5 vs. 2807 pg/ml; P =0.031, respectively) than HCV-negative patients. The level of NT-ProBNP and diastolic dysfunction showed a strong positive correlation ( P <0.001). The level of NT-ProBNP and the HCV RNA PCR level showed a significant positive correlation ( P <0.001), and the level of NT-ProBNP increased significantly as the Child–Pugh score increased ( P <0.001). Conclusion Compared to HCV-negative patients, HCV-positive dialysis patients exhibited more diastolic dysfunction and higher levels of NT-ProBNP. Additionally, HCV patients with Child–Pugh C had higher levels of NT-ProBNP than Child B and A patients, respectively.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4103/jesnt.jesnt_4_24
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.